Cargando…
Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO
We have studied the long-term toxicity of a Roundup-tolerant GM maize (NK603) and a whole Roundup pesticide formulation at environmentally relevant levels from 0.1 ppb. Our study was first published in Food and Chemical Toxicology (FCT) on 19 September, 2012. The first wave of criticisms arrived wit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044951/ https://www.ncbi.nlm.nih.gov/pubmed/27752411 http://dx.doi.org/10.1186/s12302-014-0013-6 |
_version_ | 1782457026680455168 |
---|---|
author | Séralini, Gilles-Eric Mesnage, Robin Defarge, Nicolas Spiroux de Vendômois, Joël |
author_facet | Séralini, Gilles-Eric Mesnage, Robin Defarge, Nicolas Spiroux de Vendômois, Joël |
author_sort | Séralini, Gilles-Eric |
collection | PubMed |
description | We have studied the long-term toxicity of a Roundup-tolerant GM maize (NK603) and a whole Roundup pesticide formulation at environmentally relevant levels from 0.1 ppb. Our study was first published in Food and Chemical Toxicology (FCT) on 19 September, 2012. The first wave of criticisms arrived within a week, mostly from plant biologists without experience in toxicology. We answered all these criticisms. The debate then encompassed scientific arguments and a wave of ad hominem and potentially libellous comments appeared in different journals by authors having serious yet undisclosed conflicts of interests. At the same time, FCT acquired as its new assistant editor for biotechnology a former employee of Monsanto after he sent a letter to FCT to complain about our study. This is in particular why FCT asked for a post-hoc analysis of our raw data. On 19 November, 2013, the editor-in-chief requested the retraction of our study while recognizing that the data were not incorrect and that there was no misconduct and no fraud or intentional misinterpretation in our complete raw data - an unusual or even unprecedented action in scientific publishing. The editor argued that no conclusions could be drawn because we studied 10 rats per group over 2 years, because they were Sprague Dawley rats, and because the data were inconclusive on cancer. Yet this was known at the time of submission of our study. Our study was however never attended to be a carcinogenicity study. We never used the word ‘cancer’ in our paper. The present opinion is a summary of the debate resulting in this retraction, as it is a historic example of conflicts of interest in the scientific assessments of products commercialized worldwide. We also show that the decision to retract cannot be rationalized on any discernible scientific or ethical grounds. Censorship of research into health risks undermines the value and the credibility of science; thus, we republish our paper. |
format | Online Article Text |
id | pubmed-5044951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-50449512016-10-15 Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO Séralini, Gilles-Eric Mesnage, Robin Defarge, Nicolas Spiroux de Vendômois, Joël Environ Sci Eur Commentary We have studied the long-term toxicity of a Roundup-tolerant GM maize (NK603) and a whole Roundup pesticide formulation at environmentally relevant levels from 0.1 ppb. Our study was first published in Food and Chemical Toxicology (FCT) on 19 September, 2012. The first wave of criticisms arrived within a week, mostly from plant biologists without experience in toxicology. We answered all these criticisms. The debate then encompassed scientific arguments and a wave of ad hominem and potentially libellous comments appeared in different journals by authors having serious yet undisclosed conflicts of interests. At the same time, FCT acquired as its new assistant editor for biotechnology a former employee of Monsanto after he sent a letter to FCT to complain about our study. This is in particular why FCT asked for a post-hoc analysis of our raw data. On 19 November, 2013, the editor-in-chief requested the retraction of our study while recognizing that the data were not incorrect and that there was no misconduct and no fraud or intentional misinterpretation in our complete raw data - an unusual or even unprecedented action in scientific publishing. The editor argued that no conclusions could be drawn because we studied 10 rats per group over 2 years, because they were Sprague Dawley rats, and because the data were inconclusive on cancer. Yet this was known at the time of submission of our study. Our study was however never attended to be a carcinogenicity study. We never used the word ‘cancer’ in our paper. The present opinion is a summary of the debate resulting in this retraction, as it is a historic example of conflicts of interest in the scientific assessments of products commercialized worldwide. We also show that the decision to retract cannot be rationalized on any discernible scientific or ethical grounds. Censorship of research into health risks undermines the value and the credibility of science; thus, we republish our paper. Springer Berlin Heidelberg 2014-06-24 2014 /pmc/articles/PMC5044951/ /pubmed/27752411 http://dx.doi.org/10.1186/s12302-014-0013-6 Text en © Séralini et al.; licensee Springer 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Séralini, Gilles-Eric Mesnage, Robin Defarge, Nicolas Spiroux de Vendômois, Joël Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO |
title | Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO |
title_full | Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO |
title_fullStr | Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO |
title_full_unstemmed | Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO |
title_short | Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO |
title_sort | conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a gmo |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044951/ https://www.ncbi.nlm.nih.gov/pubmed/27752411 http://dx.doi.org/10.1186/s12302-014-0013-6 |
work_keys_str_mv | AT seralinigilleseric conflictsofinterestsconfidentialityandcensorshipinhealthriskassessmenttheexampleofanherbicideandagmo AT mesnagerobin conflictsofinterestsconfidentialityandcensorshipinhealthriskassessmenttheexampleofanherbicideandagmo AT defargenicolas conflictsofinterestsconfidentialityandcensorshipinhealthriskassessmenttheexampleofanherbicideandagmo AT spirouxdevendomoisjoel conflictsofinterestsconfidentialityandcensorshipinhealthriskassessmenttheexampleofanherbicideandagmo |